Automating iPS Cell Manufacturing for Regenerative Medicine: Working Toward Truly Personalized Cell Therapies

The Automated iPSC Establishment System is unique in three main features. First, it employs a fully automated closed-system design. Since the establishment and culture of iPS cells are completed entirely inside a sealed container that is isolated from the external environment, this helps reduce the risk of contamination by microorganisms or foreign matter. This prevents variability caused by manual handling, ensuring reproducibility and consistent quality.

Second, it enables non-invasive sensing:^*4 the state of the cells can be monitored from outside the system during the culture process, without opening the culture vessel or exposing the culture environment to the outside. This avoids damaging the cells and further reduces the risk of contamination.

*4. Non-invasive sensing: Technology that measures and monitors biometric data using light, radio waves, or sound waves.

Third, iPS cells can be established from a small amount of an individual patient's blood, roughly the amount collected during a routine blood draw. This minimizes the burden on the patient. Further, as the process requires only a small volume of blood, the use of expensive reagents is reduced, helping keep overall costs down.

Furthermore, the team designed the prototype as a compact, box-shaped unit smaller than a clean bench,^*5 making it easy to install at pharmaceutical companies, biotech companies, and cell banks.^*6 The device itself has been miniaturized to manufacture iPS cells for a single patient at low cost and configured to allow multiple units to operate at the same time as needed. The housing design, which fits easily into limited spaces, makes it easier to manufacture patient-specific iPS cells.

*5. Clean bench: An enclosed workbench maintained at a specific level of cleanliness to prevent contamination by dust and microorganisms
*6. Cell bank: A facility or organization that cryopreserves and supplies cells such as iPS cells and stem cells while maintaining quality control

Currently, manufacturing iPS cells for individual patients requires considerable expense. Owaki and his team aim to significantly reduce this cost through commercialization of this device. Replacing manual labor with the device not only reduces labor costs, but it also reduces hygiene management costs associated with maintaining a sterile environment, which had been essential in manual work settings.

However, the benefits extend beyond cost savings. Yamaguchi notes that stress reduction for the people working on cell manufacturing is another significant advantage. If technicians can shift from constantly working in high-pressure cleanrooms-where even the tiniest traces of bacteria are unacceptable-to monitoring the process on screens outside, their workload drops dramatically. That change not only eases stress and fatigue, but it also helps reduce human errors.